B-ALL Cox regression reduced model for postrelapse OS
| Variables . | No. of patients (percentage of total B-ALL cohort) . | No. of events (percentage of N, number of patients) . | Univariate analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value∗ . | P value† . | HR (95% CI) . | P value∗ . | P value† . | |||
| Age at relapse | ||||||||
| 1-9 years | 875 (51.0%) | 381 (43.5%) | 1 | <.0001 | 1 | <.0001 | ||
| 10-15 years | 482 (28.1%) | 229 (47.5%) | 1.23 (1.04-1.45) | .015 | 1.36 (1.15-1.62) | .0004 | ||
| 16+ years | 358 (20.9%) | 199 (55.6%) | 1.61 (1.36-1.91) | <.0001 | 1.67 (1.38-2.01) | <.0001 | ||
| Cytogenetic group‡ | ||||||||
| Favorable | 391 (22.8%) | 112 (28.6%) | 0.45 (0.37-0.56) | <.0001 | <.0001 | 0.65 (0.52-0.81) | .0002 | .0001 |
| Neutral | 726 (42.3%) | 377 (51.9%) | 1 | 1 | ||||
| Unfavorable | 190 (11.1%) | 115 (60.5%) | 1.47 (1.19-1.81) | .0003 | 1.11 (0.89-1.39) | .37 | ||
| Unknown | 408 (23.8%) | 205 (50.2%) | 0.92 (0.78-1.09) | .36 | 1.08 (0.88-1.33) | .448 | ||
| Non-US | ||||||||
| No | 1560 (91.0%) | 749 (48.0%) | 1 | .032 | 1 | .057 | ||
| Yes | 155 (9.0%) | 60 (38.7%) | 0.75 (0.58-0.98) | — | 0.75 (0.55-1.01) | — | ||
| US median household income | ||||||||
| US ≤$50 000 | 374 (24.0%) | 196 (52.4%) | 1 | .008 (.010 trend test) | 1 | .30 (.19 trend test) | ||
| US $50 001-$65 000 | 452 (29.0%) | 228 (50.4%) | 0.91 (0.75-1.1) | .32 | 0.93 (0.77-1.13) | .47 | ||
| US $65 001-$85 000 | 379 (24.3%) | 170 (44.9%) | 0.77 (0.63-0.95) | .013 | 0.87 (0.7-1.07) | .19 | ||
| US >$85 000 | 335 (21.5%) | 143 (42.7%) | 0.73 (0.58-0.9) | .004 | 0.79 (0.63-0.99) | .038 | ||
| US Unknown | 20 (1.3%) | 12 (60.0%) | 1.36 (0.76-2.43) | .31 | 0.84 (0.46-1.51) | .56 | ||
| Race/ethnicity | ||||||||
| Hispanic all race | 452 (26.4%) | 242 (53.5%) | 1.39 (1.19-1.63) | <.0001 | .002 | 1.19 (1.01-1.41) | .043 | .45 |
| NH White | 957 (55.8%) | 418 (43.7%) | 1 | 1 | ||||
| NH Black | 115 (6.7%) | 61 (53.0%) | 1.28 (0.98-1.67) | .075 | 1.16 (0.88-1.53) | .29 | ||
| NH Asian | 52 (3.0%) | 26 (50.0%) | 1.25 (0.84-1.85) | .274 | 1.16 (0.78-1.73) | .47 | ||
| NH Other | 16 (0.9%) | 8 (50.0%) | 1.34 (0.66-2.69) | .42 | 1.01 (0.49-2.05) | .99 | ||
| Other/Unknown | 123 (7.2%) | 54 (43.9%) | 1.03 (0.77-1.36) | .86 | 1.07 (0.80-1.43) | .64 | ||
| Sites of relapse | ||||||||
| Isolated BM | 1003 (58.5%) | 537 (53.5%) | 1 | <.0001 | 1 | <.0001 | ||
| Combined BM (±CNS) | 236 (13.8%) | 96 (40.7%) | 0.65 (0.52-0.81) | .0001 | 0.73 (0.58-0.91) | .005 | ||
| Isolated CNS | 371 (21.6%) | 140 (37.7%) | 0.53 (0.44-0.64) | <.0001 | 0.32 (0.26-0.39) | <.0001 | ||
| Unknown | 7 (0.4%) | 2 (28.6%) | 0.73 (0.18-2.94) | .66 | 0.47 (0.11-1.94) | .30 | ||
| Other | 98 (5.7%) | 34 (34.7%) | 0.5 (0.35-0.71) | <.0001 | 0.54 (0.38-0.77) | .0006 | ||
| Time to relapse | ||||||||
| <18 months | 349 (20.3%) | 256 (73.4%) | 1 | <.0001 | 1 | <.0001 | ||
| 18-35 months | 546 (31.8%) | 285 (52.2%) | 0.46 (0.39-0.55) | <.0001 | 0.44 (0.37-0.53) | <.0001 | ||
| ≥36 months | 820 (47.8%) | 268 (32.7%) | 0.26 (0.22-0.31) | <.0001 | 0.18 (0.15-0.22) | <.0001 | ||
| WBC count at initial diagnosis (cells per μL) | ||||||||
| <50 000 | 1326 (77.3%) | 605 (45.6%) | 1 | <.0001 | 1 | .060 | ||
| 50 000-100 000 | 169 (9.9%) | 69 (40.8%) | 0.89 (0.69-1.14) | .35 | 0.87 (0.68-1.13) | .30 | ||
| >100 000 | 220 (12.8%) | 135 (61.4%) | 1.6 (1.33-1.93) | <.0001 | 1.23 (1.00-1.50) | .051 | ||
| Frontline induction day 29 MRD category | ||||||||
| <0.01%§ | 587 (41.1%) | 246 (41.9%) | 1 | <.0001 | 1 | .012 | ||
| 0.01% - 0.099% | 470 (32.9%) | 197 (41.9%) | 1.02 (0.85-1.23) | .83 | 0.97 (0.80-1.18) | .79 | ||
| 0.1%-0.99% | 249 (17.4%) | 141 (56.6%) | 1.54 (1.26-1.90) | <.0001 | 1.27 (1.03-1.57) | .027 | ||
| ≥1% | 123 (8.6%) | 87 (70.7%) | 2.22 (1.74-2.84) | <.0001 | 1.45 (1.12-1.88) | .005 | ||
| Unknown | 286 | 138 (48.3%) | 1.22 (0.99-1.50) | .060 | 1.15 (0.91-1.46) | .25 | ||
| Variables . | No. of patients (percentage of total B-ALL cohort) . | No. of events (percentage of N, number of patients) . | Univariate analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P value∗ . | P value† . | HR (95% CI) . | P value∗ . | P value† . | |||
| Age at relapse | ||||||||
| 1-9 years | 875 (51.0%) | 381 (43.5%) | 1 | <.0001 | 1 | <.0001 | ||
| 10-15 years | 482 (28.1%) | 229 (47.5%) | 1.23 (1.04-1.45) | .015 | 1.36 (1.15-1.62) | .0004 | ||
| 16+ years | 358 (20.9%) | 199 (55.6%) | 1.61 (1.36-1.91) | <.0001 | 1.67 (1.38-2.01) | <.0001 | ||
| Cytogenetic group‡ | ||||||||
| Favorable | 391 (22.8%) | 112 (28.6%) | 0.45 (0.37-0.56) | <.0001 | <.0001 | 0.65 (0.52-0.81) | .0002 | .0001 |
| Neutral | 726 (42.3%) | 377 (51.9%) | 1 | 1 | ||||
| Unfavorable | 190 (11.1%) | 115 (60.5%) | 1.47 (1.19-1.81) | .0003 | 1.11 (0.89-1.39) | .37 | ||
| Unknown | 408 (23.8%) | 205 (50.2%) | 0.92 (0.78-1.09) | .36 | 1.08 (0.88-1.33) | .448 | ||
| Non-US | ||||||||
| No | 1560 (91.0%) | 749 (48.0%) | 1 | .032 | 1 | .057 | ||
| Yes | 155 (9.0%) | 60 (38.7%) | 0.75 (0.58-0.98) | — | 0.75 (0.55-1.01) | — | ||
| US median household income | ||||||||
| US ≤$50 000 | 374 (24.0%) | 196 (52.4%) | 1 | .008 (.010 trend test) | 1 | .30 (.19 trend test) | ||
| US $50 001-$65 000 | 452 (29.0%) | 228 (50.4%) | 0.91 (0.75-1.1) | .32 | 0.93 (0.77-1.13) | .47 | ||
| US $65 001-$85 000 | 379 (24.3%) | 170 (44.9%) | 0.77 (0.63-0.95) | .013 | 0.87 (0.7-1.07) | .19 | ||
| US >$85 000 | 335 (21.5%) | 143 (42.7%) | 0.73 (0.58-0.9) | .004 | 0.79 (0.63-0.99) | .038 | ||
| US Unknown | 20 (1.3%) | 12 (60.0%) | 1.36 (0.76-2.43) | .31 | 0.84 (0.46-1.51) | .56 | ||
| Race/ethnicity | ||||||||
| Hispanic all race | 452 (26.4%) | 242 (53.5%) | 1.39 (1.19-1.63) | <.0001 | .002 | 1.19 (1.01-1.41) | .043 | .45 |
| NH White | 957 (55.8%) | 418 (43.7%) | 1 | 1 | ||||
| NH Black | 115 (6.7%) | 61 (53.0%) | 1.28 (0.98-1.67) | .075 | 1.16 (0.88-1.53) | .29 | ||
| NH Asian | 52 (3.0%) | 26 (50.0%) | 1.25 (0.84-1.85) | .274 | 1.16 (0.78-1.73) | .47 | ||
| NH Other | 16 (0.9%) | 8 (50.0%) | 1.34 (0.66-2.69) | .42 | 1.01 (0.49-2.05) | .99 | ||
| Other/Unknown | 123 (7.2%) | 54 (43.9%) | 1.03 (0.77-1.36) | .86 | 1.07 (0.80-1.43) | .64 | ||
| Sites of relapse | ||||||||
| Isolated BM | 1003 (58.5%) | 537 (53.5%) | 1 | <.0001 | 1 | <.0001 | ||
| Combined BM (±CNS) | 236 (13.8%) | 96 (40.7%) | 0.65 (0.52-0.81) | .0001 | 0.73 (0.58-0.91) | .005 | ||
| Isolated CNS | 371 (21.6%) | 140 (37.7%) | 0.53 (0.44-0.64) | <.0001 | 0.32 (0.26-0.39) | <.0001 | ||
| Unknown | 7 (0.4%) | 2 (28.6%) | 0.73 (0.18-2.94) | .66 | 0.47 (0.11-1.94) | .30 | ||
| Other | 98 (5.7%) | 34 (34.7%) | 0.5 (0.35-0.71) | <.0001 | 0.54 (0.38-0.77) | .0006 | ||
| Time to relapse | ||||||||
| <18 months | 349 (20.3%) | 256 (73.4%) | 1 | <.0001 | 1 | <.0001 | ||
| 18-35 months | 546 (31.8%) | 285 (52.2%) | 0.46 (0.39-0.55) | <.0001 | 0.44 (0.37-0.53) | <.0001 | ||
| ≥36 months | 820 (47.8%) | 268 (32.7%) | 0.26 (0.22-0.31) | <.0001 | 0.18 (0.15-0.22) | <.0001 | ||
| WBC count at initial diagnosis (cells per μL) | ||||||||
| <50 000 | 1326 (77.3%) | 605 (45.6%) | 1 | <.0001 | 1 | .060 | ||
| 50 000-100 000 | 169 (9.9%) | 69 (40.8%) | 0.89 (0.69-1.14) | .35 | 0.87 (0.68-1.13) | .30 | ||
| >100 000 | 220 (12.8%) | 135 (61.4%) | 1.6 (1.33-1.93) | <.0001 | 1.23 (1.00-1.50) | .051 | ||
| Frontline induction day 29 MRD category | ||||||||
| <0.01%§ | 587 (41.1%) | 246 (41.9%) | 1 | <.0001 | 1 | .012 | ||
| 0.01% - 0.099% | 470 (32.9%) | 197 (41.9%) | 1.02 (0.85-1.23) | .83 | 0.97 (0.80-1.18) | .79 | ||
| 0.1%-0.99% | 249 (17.4%) | 141 (56.6%) | 1.54 (1.26-1.90) | <.0001 | 1.27 (1.03-1.57) | .027 | ||
| ≥1% | 123 (8.6%) | 87 (70.7%) | 2.22 (1.74-2.84) | <.0001 | 1.45 (1.12-1.88) | .005 | ||
| Unknown | 286 | 138 (48.3%) | 1.22 (0.99-1.50) | .060 | 1.15 (0.91-1.46) | .25 | ||
Bold values indicate P < .05.
BM, bone marrow.
P value for each subcategory of a variable in comparison with the reference group.
P value for the overall test for a variable.
Cytogenetic group was defined as the following: favorable (double trisomy 4/10, ETV6::RUNX1) vs unfavorable (KMT2A-rearranged, hypodiploid <44, intrachromosomal amplification of chromosome 21, BCR::ABL1) vs neutral (all others).
This category included patients with MRD <0.01% and a small number of patients whose MRD was reported as negative using an assay with a sensitivity of 1 in 1000.